Vaxxinity (VAXX) 10-Q 10 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 08, 2022
Document Type	10-Q
Entity Central Index Key	0001851657
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-41058
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line Two	Ste 3388
Entity Address, Address Line One	1717 Main St
Entity Address, City or Town	Dallas
Entity Address, Postal Zip Code	75201
Entity Address, State or Province	TX
Entity Tax Identification Number	86-2083865
Entity Registrant Name	Vaxxinity, Inc.
Entity Ex Transition Period	false
Local Phone Number	254
City Area Code	244-5739
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	VAXX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Class A Common Stock [Member]
Entity Common Stock, Shares Outstanding		112,181,870
Common Class B [Member]
Entity Common Stock, Shares Outstanding		13,874,132

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 18,875	$ 144,885
Short-term investments	80,233
Restricted Cash	3,073	172
Amounts due from related parties	400	393
Prepaid expenses and other current assets	5,502	8,851
Total current assets	108,083	154,301
Property and equipment, net	12,801	12,372
Long-term deposits	2,076
Total assets	122,960	166,673
Current liabilities:
Accounts payable	3,319	3,192
Amounts due to related parties	16,676	19,407
Accrued expense and other current liabilities	12,049	4,519
Notes payable	387	376
Total current liabilities	32,431	27,494
Other liabilities
Notes payable, net of current portion	10,032	10,323
Other long-term liabilities	236	237
Total liabilities	42,699	38,054
Preferred stock: $0.0001 par value, 50,000,000 shares authorized at September 30, 2022 and December 31, 2021	0	0
Stockholders' equity:
Additional paid-in capital	364,445	357,822
Accumulated other comprehensive income (loss)	(215)
Accumulated deficit	(284,247)	(229,481)
Total stockholders equity	80,261	128,619
Total liabilities and stockholders equity	122,960	166,673
Class A Common Stock [Member]
Stockholders' equity:
Common stock:	278	278
Common Class B [Member]
Stockholders' equity:
Common stock:	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized/designated	50,000,000	50,000,000
Class A Common Stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	112,181,870	111,518,094
Common stock, shares outstanding	112,181,870	111,518,094
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,874,132	13,874,132
Common stock, shares outstanding	13,874,132	13,874,132

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Consolidated Statements of Income [Abstract]
Revenue				$ 67
Cost of revenue		$ 9		1,937
Gross (loss) profit		41		(1,870)
Operating expenses:
Research and development	$ 12,468	23,443	$ 34,609	54,324
General and administrative	7,300	6,873	20,546	21,130
Total operating expenses	19,768	30,316	55,155	75,454
Loss from operations	(19,768)	(30,275)	(55,155)	(77,324)
Other (income) expense:
Interest and other expense	54	112	264	732
Interest and other income	545	3	625	6
Change in fair value of convertible notes				2,667
Change in fair value of simple agreements for future equity				8,365
Change in fair value of warrant liability				214
(Gain) loss on foreign currency translation, net	(25)	5	(28)	24
Other (income) expense	516	(114)	389	(11,996)
Net loss	$ (19,252)	$ (30,389)	$ (54,766)	$ (89,320)
Net loss per share, basic and diluted	$ (0.15)	$ (0.44)	$ (0.43)	$ (1.30)
Weighted average common shares outstanding, basic and diluted	126,036,865	68,728,509	125,899,557	68,667,682
Other comprehensive income (loss):
Unrealized gain (loss) on investments	$ (215)		$ (215)
Other comprehensive income (loss)	$ (215)		$ (215)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Class A Common Stock [Member]	Class B Common Stock [Member]	Common Stock [Member] Class A Common Stock [Member]	Common Stock [Member] Class B Common Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member] Series Seed Stock [Member]	Preferred Stock [Member] Series Seed-1 Stock [Member]	Preferred Stock [Member] Series Seed-2 Stock [Member]	Preferred Stock [Member] Series A-1 Stock [Member]	Preferred Stock [Member] Series A-2 Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] SAFEs [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Convertible Debt [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Notes Payable, Related Parties [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Treasury Stock [Member]	Additional Paid In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020	$ (87,352)			$ 272		$ 62,475	$ 10,383	$ 20,903	$ 11,315	$ 4,640	$ 15,234	$ 0					$ 0	$ (23)	$ 4,682		$ (92,306)
Beginning balance, common shares at Dec. 31, 2020				60,360,523	10,999,149													3,169,093
Beginning balance, preferred shares at Dec. 31, 2020							7,831,528	22,876,457	14,615,399	1,871,511	6,307,690	0					0
Issuance of common stock upon exercise of stock options, shares				82,696
Issuance of common stock upon exercise of stock options	70																		70
Issuance of stock, shares				485,836													15,365,574
Issuance of stock	103																$ 122,791		103
Exhange of preferred stock, shares							(7,831,528)	(22,876,457)	(14,615,399)	(1,871,511)	(6,307,690)	53,502,585
Exchange of preferred stock							$ (10,383)	$ (20,903)	$ (11,315)	$ (4,640)	$ (15,234)	$ 62,475
Conversion of stock, shares													4,539,060	134,106	3,624,114	423,230
Conversion of stock													$ 35,600	$ 614	$ 27,379	$ 2,138
Vesting of restricted stock, shares				15,405
Retirement of treasury stock in merger, shares				3,169,093														3,169,093
Retirement of treasury stock in merger	23																	$ (23)	23
Stock-based compensation expense	5,602																		5,602
Reclassification of common stock to Class A, shares				(2,874,983)	2,874,983
Net loss	(89,320)																				(89,320)
Ending balance at Sep. 30, 2021	(170,920)			$ 272		$ 250,997	$ 0	$ 0	$ 0	$ 0	$ 0	$ 128,206					$ 122,791	$ 0	10,434		(181,626)
Ending balance, common shares at Sep. 30, 2021				54,900,384	13,874,132
Ending balance, preferred shares at Sep. 30, 2021							0	0	0	0	0	62,223,095					15,365,574
Ending balance, treasury shares at Sep. 30, 2021																		0
Beginning balance at Dec. 31, 2021	$ 128,619			$ 278															357,822		(229,481)
Beginning balance, common shares at Dec. 31, 2021		111,518,094	13,874,132	111,518,094	13,874,132
Issuance of common stock upon exercise of stock options, shares	1,065,706			663,776
Issuance of common stock upon exercise of stock options	$ 262																		262
Stock-based compensation expense	6,361																		6,361
Net loss	(54,981)																			$ (215)	(54,766)
Ending balance at Sep. 30, 2022	$ 80,261			$ 278															$ 364,445	$ (215)	$ (284,247)
Ending balance, common shares at Sep. 30, 2022		112,181,870	13,874,132	112,181,870	13,874,132

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Equity (Parenthetical) $ in Thousands	Sep. 30, 2021 USD ($)
Preferred Stock [Member] | Series B Preferred Stock [Member]
Issuance of stock, issuance costs	$ 131

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (54,766)	$ (89,320)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,144	928
Amortization of debt issuance costs	40	234
Amortization of discount on short-term investments	(422)
Stock-based compensation expense	6,361	5,704
Non-cash consulting expense		268
Change in fair value of convertible notes		2,667
Change in fair value of warrant liability		214
Change in fair value of simple agreements for future equity		8,365
Changes in operating assets and liabilities:
Accounts receivable		26
Amounts due to related parties	(7)	(18)
Prepaid expenses and other current assets	3,349	(10,155)
Long-term deposits	(2,076)
Deferred offering costs		(3,935)
Accounts payable	127	2,888
Amounts due to related parties	(2,731)	13,212
Accrued expenses and other current liabilities	7,530	4,521
Other liabilities	0	(2,625)
Net cash used in operating activities	(41,451)	(67,026)
Cash flows from investing activities:
Purchase of short-term investments	(107,526)
Redemption of short-term investments	27,500
Purchase of property and equipment	(1,574)	(50)
Net cash used in investing activities	(81,600)	(50)
Cash flows from financing activities:
Proceeds from issuance of convertible notes payable with related parties		2,000
Repayment of convertible notes		(2,000)
Repayment of notes payable	320	96
Repayment of note payable with related party		(100)
Repayment of Paycheck Protection Program		(257)
Proceeds from issuance of simple agreement for future equity		2,900
Proceeds from exercise of stock options	262	70
Net cash provided by financing activities	(58)	125,308
Increase in cash, cash equivalents, and restricted cash	(123,109)	58,232
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	145,057	31,217
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	21,948	89,449
Supplemental Disclosure
Cash paid for interest	$ 277	288
Noncash Financing Activities
Reitrement Of Treasury Shares		23
Series B Preferred Stock [Member]
Changes in operating assets and liabilities:
Proceeds from issuance of convertible preferred stock, net of issuance costs		122,791
Noncash Financing Activities
Conversion Of Stock Amount Issued 1		122,900
Simple Agreement for Future Equity [Member]
Noncash Financing Activities
Conversion Of Stock Amount Issued 1		2,205
Series Seed, Series Seed-1, Series Seed-2, Series A-1 and Series A-2 for Series A [Member]
Noncash Financing Activities
Conversion Of Stock Amount Issued 1		62,475
Convertible Notes Payable to Series A Preferred [Member]
Noncash Financing Activities
Conversion Of Stock Amount Issued 1		27,545
Notes Payble to Series A Preferred [Member]
Noncash Financing Activities
Conversion Of Stock Amount Issued 1		35,600
Warrant to Series A Preferred [Member]
Noncash Financing Activities
Conversion Of Stock Amount Issued 1		$ 614

Nature of the Business

Nature of the Business	9 Months Ended
	Sep. 30, 2022
Nature of the Business [Abstract]
Nature of the Business	1. Nature of the Business Vaxxinity, combination of from UBI in and a second spin-out (“COVAXX”). and on March 2, 2021, did so by exchange contributed their equity interests in each of UNS and COVAXX The Company is a pain, cardiovascular diseases by prophylactic and therapeutic a heterologous booster party. The Company limited competitors of new of proprietary technology, successfully achieve profitability. The including extensive pre-clinical and clinical testing and amounts of assurance that intellectual property approved products will be commercially viable. if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and is dependent upon the services of its employees and consultants. Contribution and Exchange Agreement On March preferred stock and options to common stock in Vaxxinity, for a warrant to acquire common stock in Vaxxinity contributed to Vaxxinity • Each UNS common share and convertible preferred share was exchanged 0.2191 Series A preferred stock, as applicable; • Each share of COVAXX 3.4233 stock or Series A preferred stock, as applicable (and prior to the closing of the Reorganization, COVAXX then exchanged for shares of Vaxxinity’s • The Reorganization Convertible Notes were exchanged 4,047,344 preferred stock; and • Each outstanding option of both UNS and COVAXX substituted with an option to purchase shares of Class A common stock of exchanged based on a conversion ratio of 0.2191 . Each outstanding COVAXX ratio of 3.4233 . All parties to exchange for Vaxxinity’s that is governed by Section 351(a) of the Internal Revenue Code of 1986, as amended. The Reorganization liabilities Reorganization are presented on a consolidated basis. Reverse Stock Split On October 29, 1.556 Class B common the Company’s amounts financial fractional shares that would have resulted from the Stock Split have been rounded down Initial Public Offering On November 15, 2021, the Company closed its IPO of 6,000,000 13.00 per share. On 537,711 common stock pursuant 900,000 stock at after deducting underwriting discounts 71.1 million. Upon the closing automatically converted at the same ratio used for the Stock Split (1-for- 1.556 ) into shares of its Class A common stock. Liquidity As of September 30, 2022, the 102.2 18.9 and 80.2 3.1 3.0 restricted for the reimbursement of date, the Company has primarily financed its operations through the under promissory foundations Company has experienced 54.8 the nine $ 41.5 284.2 to incur statements were available to be issued, the Company expects its existing cash and cash equivalents to be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months. In order occur through funding may not continue to advance commercialization efforts prefer to develop and market itself. The contemplates consolidated amounts or the amounts and classification of liabilities that might result from

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The accounting principles in the United States of America (GAAP) and Exchange Commission (“SEC”) for interim financial periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share the conversion ratios determined under the Contribution and Exchange Agreement These interim (consisting of normal consolidated balance sheet at December 31, 2021, has been derived from the for necessarily indicative of the results information and footnote generally reporting of the and notes thereto included in our report for the year ended December 31, 2021. Leases At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we either liabilities in our Condensed Consolidated Balance Sheets. Lease recognition occurs the lease term. Our lease that determining the present value of term, and lease liabilities represent our obligation to make lease payments under the lease. ROU assets also include any lease payments made prior basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, is a transfer of title or purchase option reasonably generally accounted for together as a single lease component. a lease term of 12 months or less, which does not subject the leases to capitalization. Short-term investments The investments are fund consolidated balance sheets if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. Available-for-sale income amortization or accretion of discounts and premiums on investments are included Available-for-sale may indicate impairment. must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will the security’s amortized cost basis. to its fair market as accumulated other comprehensive income. The Company did not record any such impairments during the period ending Related party transactions The Company has a Related to including the proposed aggregate the benefits assessment of unrelated third parties. Under the policy, related party transactions are approved only if the Committee determines in good faith that the transaction is not inconsistent with the interests of the Company and its shareholders. Significant accounting policies The significant accounting policies used in preparation of these unaudited our accounting policies during the three and nine months ended September Recently issued accounting pronouncements From time Company standards that are not yet effective will not have a material impact on Recently adopted accounting standards In provided an alternative method in addition to the modified retrospective transition method for ASU No. 2016-02, Leases: Amendments to the FASB to initially retained earnings in the of more than Companies for fiscal years beginning after December 15, 2021. The Company apply the the comparative balance of accumulated deficit on the date of adoption. The Company has elected to combine lease components (for example fixed rent payments) embedded reassess under the new standard the Company’s In addition, the Company also elected the elect the based on all facts and circumstances through the effective Results for reporting adjusted standard, on January lease liability.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Measurements [Abstract]
Fair Value Measurements	3. Fair Value The Company's money in active markets for identical assets. The following indicate the level of the fair value hierarchy used to determine such fair values (in During the three Level 1, Level 2 and Level 3. December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794 September 30, 2022 Level 1 Level 2 Level 3 Total Assets: Short-term investments 80,233 — — 80,233 Money market accounts 10,995 — — 10,995 Total assets $ 91,228 $ — $ — $ 91,228

Short-Term Investments

Short-Term Investments	9 Months Ended
	Sep. 30, 2022
Short-Term Investments [Abstract]
Short-term investments	4. Short-Term As of September 30, 2022, the Company’s These securities mature in less than 1 year. As of September 30, 2022 Amortized Cost Unrealized Gains (Losses), Net Recorded Basis U.S. Treasury Securities $ 80,448 $ (215) $ 80,233 Total $ 80,448 $ (215) $ 80,233

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, 2022 2021 Prepaid materials and supplies $ 1,754 $ 3,517 Clinical prepayments 2,067 4,379 Deposits 1,323 614 Other 358 341 $ 5,502 $ 8,851 The Company’s prepaid material and supplies related to enzyme-linked immunosorbent assay (“ELISA”) test 1.7 million was paid to a related 0.7

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2022
Property and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment, net consisted of the following (in thousands): September 30, December 31, 2022 2021 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 2,790 1,831 Software 169 168 Facilities, furniture and fixtures 106 85 Vehicles 87 87 Fixed assets not yet placed into service 791 199 Total property 15,926 14,353 Less: accumulated depreciation (3,125) (1,981) Property and equipment, net $ 12,801 $ 12,372 Depreciation 0.4 1.1 Depreciation expense for the three and nine months ended September 0.4 0.9

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in Accrued external 3.0 September 30, 2022 not yet applied against research and development expense. September 30, December 31, 2022 2021 Accrued external research and development $ 3,842 $ 1,501 Accrued bonuses 3,410 2,294 Accrued professional fees and other 4,767 692 Accrued interest 30 32 $ 12,049 $ 4,519

Other Long-Term Liabilities

Other Long-Term Liabilities	9 Months Ended
	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	8. Other Long-Term Other long-term liabilities consisted of the following (in thousands): September 30, December 31, 2022 2021 Accrued tax provision 236 236 Accrued rent — 1 $ 236 $ 237 As of 0.2 interest the Company may be subject to be forgiven but has accrued for them until the statute of limitations

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Notes payable with related parties [Abstract]
Notes payable with related parties [Text Block]	9. Notes Payable Note Payable—Airplane In connection with for $ 11.5 3.4 % and a maturity date of June monthly in the amount of $ 0.1 9.4 of the Company. In addition, the Company 0.3 loan. There are no financial covenants associated with the 2025 Note. The carrying value of the 2025 Note is as follows (in thousands): As of September 30, 2022, the remaining principal payments for the 2025 Interest expense 0.1 0.3 2022, 0.1 0.3 ended September 30, 2021, 0.1 expenses and December 31, 2021. Note Payable—Paycheck Protection Program The Company Association (“HSBC”) 0.3 Program (“PPP”). for loans to qualifying businesses for amounts up to 2.5 times of the average The Company paid off the PPP Loan in full, including all accrued September 30, December 31, 2022 2021 Principal $ 10,564 $ 10,883 Unamortized debt issuance cost (145) (184) Carrying amount 10,419 10,699 Less: current portion (387) (376) Note payable, net of current portion and debt issuance cost $ 10,032 $ 10,323 Amount 2022 $ 109 2023 444 2024 458 2025 9,553 $ 10,564

Convertible Preferred Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2022
Convertible preferred stock [Abstract]
Convertible preferred stock	10. Convertible Preferred Stock In connection with 0.2191 stock and 3.4233 the first 122.9 stock financing. The 15,365,574 8.00 preferred stock converted As 50,000,000 0.0001 September 30, 2022 and December 31, 2021.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2022
Common Stock [Abstract]
Common Stock	11. As explained common 60,360,523 Vaxxinity’s 10,999,149 was exchanged 0.2191 3.4233 shares of Vaxxinity Vaxxinity’s 1,100,000,000 stock 0.0001 1,000,000,000 100,000,000 Holders of Class as otherwise expressly provided in Vaxxinity’s law, holders of our Class B common stock will be entitled to ten votes per share on all Holders stockholders, except (i) amendments value amendment preferences or special rights would be required to vote separately to approve the proposed amendment. Holders of common legally available therefor if the board of directors, in its discretion, determines to issue dividends. The Company has reserved shares of common stock for issuance for the following September 30, December 31, 2022 2021 Options and RSUs issued and outstanding 20,593,681 21,387,909 Options available for future grants 6,251,916 7,209,538 Warrants issued and 1,928,020 1,928,020 28,773,617 30,525,467

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Stock-Based Compensation [Abstract]
Stock-Based Compensation	12. Stock-Based Compensation 2021 Omnibus Incentive Compensation Plan In Company restricted stock units, performance awards, cash incentive awards and The maximum number of shares of common stock that can be issued under the Plan is 8,700,000 automatically 4 % of outstanding Compensation Committee, if any preceding calendar year, net of the shares Stock Options As of 13,931,226 6,362,455 Class B 9,032,635 4,944,763 2022, the maximum number of stock options awards available for 6,251,916 . The following table summarizes stock option activity during the nine The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the common stock for those options that had exercise prices lower than the fair The intrinsic value of options exercised during the nine months ended 4.5 The weighted-average grant-date fair value per share of options granted 2.38 . Restricted Stock The following table summarizes the Company’s Stock-based compensation expense 0.1 2022. Stock-Based Compensation Expense The condensed consolidated statements of operations (in thousands): As of September 30, 2022, 18.9 is expected to be recognized over a weighted average period of 2.5 Number of Stock Options Outstanding Weighted Exercise Price Per Share Weighted Contractual Term Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Granted 1,104,921 3.19 Exercised (1,065,706) 3.26 Forfeited (1,133,443) 7.23 Balance at September 30, 2022 20,293,681 $ 5.13 7.1 $ 11,940 Options vested and exercisable at September 30, 2022 13,977,398 $ 4.52 6.8 $ 10,773 Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2021 — $ — Issued 300,000 3.76 Unvested at September 30, 2022 300,000 $ 3.76 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 General and administrative $ 1,509 $ 1,100 $ 3,888 $ 4,864 Research and development 848 364 2,473 738 Total stock-based $ 2,357 $ 1,464 $ 6,361 $ 5,602

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Taxes [Abstract]
Income Taxes	13. Income Taxes The Company computes its basis, permanent book to tax differences; impacts from tax audits with state, federal or foreign tax authorities; impacts from tax law changes; or change in judgment as to the realizability of deferred tax assets. The Company identifies items which are unusual and non-recurring in nature and treats these The Company’s effective 0.00 %, due primarily to its uncertainty of realizing a benefit from net operating losses incurred during the period. In assessing recorded deferred taxable income in the periods in which of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on these items and the consecutive years of pretax losses (resulting from impairment), management determined that enough uncertainty to jurisdictions. The Company files numerous foreign jurisdictions to four years from when the return is filed. As of September 30, 2022, the The carryforwards is limited under Section our capital ownership rules generally including certain public “groups” of from certain periods. At this time, allow us to realize these NOL carryforwards.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Net Loss Per Share [Abstract]
Net Loss Per Share	14. Net Loss Per Share The Company’s unvested restricted The convertible net loss per share. loss per share is the each period including them would have had an anti-dilutive effect: September 30, September 30, 2022 2021 Series A preferred stock — 39,989,083 Series B preferred stock — 9,875,037 Options and RSUs issued and outstanding 20,593,681 20,714,308 Warrants issued and 1,928,020 2,056,722 22,521,701 72,635,150

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Contractual Obligations The Company and contract manufacturing organizations and CMOs are generally cancellable, with notice, at the Company’s As of September 30, 2022, the Company had remaining prepayments to CROs of $ 3.1 $ 0.7 product candidate. Michael J. Fox Foundation Grant On November 3, the amount of $ 0.8 UB-312, an a -Synuclein immunotherapy. and expected to be received in tranches over a two-year twelve months, the funds received are recognized as a short-term accrued liability. reduction of research and development expenses, in the same period as the As 0.1 September through the grant. Coalition for Epidemic Preparedness Innovations (“CEPI”) Grant In April CEPI has 9.3 COVID-19 vaccine candidate is evaluating the ability of UB-612 Omicron - in people aged 16 years or older, who The Company will also be performing further manufacturing scale-up the terms of the COVID-19 Vaccines Cash payments received in advance under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the funding agreement are received in each tranche are expected to the utilized within twelve months, the funds received are reflected within restricted cash with a corresponding short-term accrued liability. expenses, in the same period as the expenses that the grant is intended to reimburse are incurred. As of the restricted 3.0 Company recognized a reduction of $ 1.6 3.1 Lease Agreements In April 2022, the 4,419 lease commenced in April 2022 guidance found in ASC 842. landlord have the which does not subject the New York The Company’s 0.1 0.1 during the three months 0.3 0.1 expense during the nine months ended September 30, 2022. License Agreements In August 2021, that expanded intellectual property obtained a make, have made, utilize, import, based vaccines in the field of all virus (HIV), herpes simplex virus (HSE) and Immunoglobulin E (IgE). The patents and patent applications License Agreement include claims directed to a CpG delivery system, artificial T helper cell epitopes and certain designer peptides and proteins utilized warrant to purchase Class A common stock (the “UBI Warrant”) The Company considered ASC 805, “Business Combinations” (“ASC 805”) and ASC 730, in determining how to account to a related party in exchange for a license agreement. were held control transaction, party did not have any basis in the assets licensed, there was no accounting impact for Indemnification Agreements In the vendors, lessors, breach of such agreements into indemnification other things, to indemnify them maximum potential amount many cases, unlimited. To not aware of any flows, and it has not accrued any liabilities related to such obligations as of September Legal Proceedings From September 30, 2022 and December 31, 2021, the Company was not a party Loss Contingency In April 2021, the Company engaged United Biopharma, Inc. (UBP) to begin acquiring raw materials for use in the production of GMP grade recombinant protein for UB-612, our Covid vaccine candidate. 7.2 3 million of 1.2 these raw materials were used to produce proteins. Upon rejection of 30, 2022, $ 0.4 0.8 3.0 management suppliers are still ongoing. For the $ 2.6 expense.

Benefit Plans

Benefit Plans	9 Months Ended
	Sep. 30, 2022
Benefit Plans [Abstract]
Benefit Plans	16. Benefit Plans In substantially all annual compensation on a pre-tax basis. The Company does not make matching The Company offers portion of their annual compensation. The 4 % of each participant’s annual salary. During both of the three and nine months ended September 30, 2022 and 2021, the 0.1

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	17. Related Party Transactions The Company has related party arrangements with UBI Asia (“UBI-Asia”), UBI Pharma, Inc. (“UBI-P”), United BioPharma, As of September 30, 2022 UBI owned 44 % of the Company’s stock. The majority of the voting interests in both UBI and the Company were held by a group of immediate family members, These related parties are governed by various Master Services Agreements UBI MSA - UBI provides research, development and clinical functions to the Company. with UBI for the production and shipment of the Company’s UBIA MSA - UBI-Asia for manufacturing, quality control, testing, validation, UBP MSA - United BioPharma, Inc provide the Company with manufacturing, COVID MSA (“COVID the services to the Company. COVID-19 technologies related to diagnostics, vaccines, and therapies for Asia development and manufacturing services to the Company. Total 16.7 19.4 respectively. 0.4 0.4 2021, respectively. Total 0.0 13.9 2021, respectively. 1.1 32.6 2021, respectively. Total related party operating September 30, December 31, 2022 2021 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 1,743 $ 3,517 Amounts due from related parties 400 393 Property and equipment, net — 337 Liabilities Amounts due to related parties 16,676 19,407 Accrued expenses 877 — Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating expenses Research and development Services provided by related parties — 13,515 1,139 38,667 Taiwan CDC grant reimbursement — — — (7,199) General and administrative Services provided by related parties $ — $ 355 $ — $ 1,173

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2022
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The accounting principles in the United States of America (GAAP) and Exchange Commission (“SEC”) for interim financial periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share the conversion ratios determined under the Contribution and Exchange Agreement These interim (consisting of normal consolidated balance sheet at December 31, 2021, has been derived from the for necessarily indicative of the results information and footnote generally reporting of the and notes thereto included in our report for the year ended December 31, 2021.
Foreign currency translation	Significant accounting policies The significant accounting policies used in preparation of these unaudited our accounting policies during the three and nine months ended September
Recently Adopted and Issued Accounting Pronouncements	Recently issued accounting pronouncements From time Company standards that are not yet effective will not have a material impact on Recently adopted accounting standards In provided an alternative method in addition to the modified retrospective transition method for ASU No. 2016-02, Leases: Amendments to the FASB to initially retained earnings in the of more than Companies for fiscal years beginning after December 15, 2021. The Company apply the the comparative balance of accumulated deficit on the date of adoption. The Company has elected to combine lease components (for example fixed rent payments) embedded reassess under the new standard the Company’s In addition, the Company also elected the elect the based on all facts and circumstances through the effective Results for reporting adjusted standard, on January lease liability.
Lessee Leases [Policy Text Block]	Leases At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we either liabilities in our Condensed Consolidated Balance Sheets. Lease recognition occurs the lease term. Our lease that determining the present value of term, and lease liabilities represent our obligation to make lease payments under the lease. ROU assets also include any lease payments made prior basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, is a transfer of title or purchase option reasonably generally accounted for together as a single lease component. a lease term of 12 months or less, which does not subject the leases to capitalization.
Related Party Transactions [Policy Text Block]	Related party transactions The Company has a Related to including the proposed aggregate the benefits assessment of unrelated third parties. Under the policy, related party transactions are approved only if the Committee determines in good faith that the transaction is not inconsistent with the interests of the Company and its shareholders.
Short-Term Investments [Policy Text Block]	Short-term investments The investments are fund consolidated balance sheets if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. Available-for-sale income amortization or accretion of discounts and premiums on investments are included Available-for-sale may indicate impairment. must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will the security’s amortized cost basis. to its fair market as accumulated other comprehensive income. The Company did not record any such impairments during the period ending

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Measurements [Abstract]
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794 September 30, 2022 Level 1 Level 2 Level 3 Total Assets: Short-term investments 80,233 — — 80,233 Money market accounts 10,995 — — 10,995 Total assets $ 91,228 $ — $ — $ 91,228

Short-Term Investments (Tables)

Short-Term Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Short-Term Investments [Abstract]
Short-Term Investments	As of September 30, 2022 Amortized Cost Unrealized Gains (Losses), Net Recorded Basis U.S. Treasury Securities $ 80,448 $ (215) $ 80,233 Total $ 80,448 $ (215) $ 80,233

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	September 30, December 31, 2022 2021 Prepaid materials and supplies $ 1,754 $ 3,517 Clinical prepayments 2,067 4,379 Deposits 1,323 614 Other 358 341 $ 5,502 $ 8,851

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Property and Equipment [Abstract]
Property and Equipment, Net	September 30, December 31, 2022 2021 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 2,790 1,831 Software 169 168 Facilities, furniture and fixtures 106 85 Vehicles 87 87 Fixed assets not yet placed into service 791 199 Total property 15,926 14,353 Less: accumulated depreciation (3,125) (1,981) Property and equipment, net $ 12,801 $ 12,372

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued expenses and other current liabilities	September 30, December 31, 2022 2021 Accrued external research and development $ 3,842 $ 1,501 Accrued bonuses 3,410 2,294 Accrued professional fees and other 4,767 692 Accrued interest 30 32 $ 12,049 $ 4,519

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities	September 30, December 31, 2022 2021 Accrued tax provision 236 236 Accrued rent — 1 $ 236 $ 237

Notes payable (Tables)

Notes payable (Tables)	9 Months Ended
	Sep. 30, 2022
Notes payable with related parties [Abstract]
Schedule of Maturities of Notes Payable	Amount 2022 $ 109 2023 444 2024 458 2025 9,553 $ 10,564
Schedule Of Carrying Values And Estimated Fair Values Of Debt Instruments [Table Text Block]	September 30, December 31, 2022 2021 Principal $ 10,564 $ 10,883 Unamortized debt issuance cost (145) (184) Carrying amount 10,419 10,699 Less: current portion (387) (376) Note payable, net of current portion and debt issuance cost $ 10,032 $ 10,323

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2022
Common Stock [Abstract]
Reserved Shares of Common Stock for Issuance	September 30, December 31, 2022 2021 Options and RSUs issued and outstanding 20,593,681 21,387,909 Options available for future grants 6,251,916 7,209,538 Warrants issued and 1,928,020 1,928,020 28,773,617 30,525,467

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Stock-Based Compensation [Abstract]
Summary of Stock Option Activity	Number of Stock Options Outstanding Weighted Exercise Price Per Share Weighted Contractual Term Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Granted 1,104,921 3.19 Exercised (1,065,706) 3.26 Forfeited (1,133,443) 7.23 Balance at September 30, 2022 20,293,681 $ 5.13 7.1 $ 11,940 Options vested and exercisable at September 30, 2022 13,977,398 $ 4.52 6.8 $ 10,773
Summary of Restricted Stock Activity	Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2021 — $ — Issued 300,000 3.76 Unvested at September 30, 2022 300,000 $ 3.76
Schedule of Stock-Based Compensation Expense for Stock Options	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 General and administrative $ 1,509 $ 1,100 $ 3,888 $ 4,864 Research and development 848 364 2,473 738 Total stock-based $ 2,357 $ 1,464 $ 6,361 $ 5,602

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Net Loss Per Share [Abstract]
Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share	September 30, September 30, 2022 2021 Series A preferred stock — 39,989,083 Series B preferred stock — 9,875,037 Options and RSUs issued and outstanding 20,593,681 20,714,308 Warrants issued and 1,928,020 2,056,722 22,521,701 72,635,150

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Operating Activity	September 30, December 31, 2022 2021 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 1,743 $ 3,517 Amounts due from related parties 400 393 Property and equipment, net — 337 Liabilities Amounts due to related parties 16,676 19,407 Accrued expenses 877 — Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating expenses Research and development Services provided by related parties — 13,515 1,139 38,667 Taiwan CDC grant reimbursement — — — (7,199) General and administrative Services provided by related parties $ — $ 355 $ — $ 1,173

Nature of the Business (Narrati

Nature of the Business (Narrative) (Details) $ / shares in Units, $ in Thousands				3 Months Ended		9 Months Ended
	Nov. 18, 2021 $ / shares shares	Nov. 15, 2021 $ / shares shares	Oct. 29, 2021	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) shares
Nature of Business Disclosures [Line Items]
Proceeds from issuance of simple agreement for future equity							$ 2,900
Proceeds from issuance of convertible notes payable with related parties							2,000
Repayment of convertible notes							2,000
Cash and cash equivalents				$ 18,875		$ 18,875		$ 144,885
Net Income Loss				(19,252)	$ (30,389)	(54,766)	(89,320)
Accumulated deficit				(284,247)		(284,247)		(229,481)
Reverse stock split	1.556		1.556
Restricted Cash Current				3,073		3,073		$ 172
Net Cash Provided By Used In Operating Activities						(41,451)	$ (67,026)
Liquid Assets				102,200		102,200
Short Term Investments				80,233		80,233
UB-612 [Member]
Nature of Business Disclosures [Line Items]
Restricted Cash Current				$ 3,000		$ 3,000
Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares | shares		6,000,000
Share Price | $ / shares		$ 13
Underwriters [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares | shares	900,000
Underwriters [Member] | Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares | shares	537,711
Share Price | $ / shares	$ 71.1
UNS. [Member]
Nature of Business Disclosures [Line Items]
Note conversion ratio						3.4233
Option exchange ratio				0.2191
COVAXX [Member]
Nature of Business Disclosures [Line Items]
ConvertiblePreferredStockSharesIssuedUponConversion | shares								3.4233
Debt Conversion Converted Instrument Shares Issued 1 | shares						4,047,344

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short Term Investments	$ 80,233
Cash and cash equivalents	18,875	$ 144,885
Assets	91,228	139,794
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	10,995	139,794
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short Term Investments	80,233
Assets	91,228	139,794
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 10,995	$ 139,794

Short-Term Investments (Details

Short-Term Investments (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Cash And Cash Equivalents [Line Items]
Amortized Cost	$ 80,448
Unrealized Gains (Losses), Net	(215)
Recorded Basis	80,233
U S Treasury Securities [Member]
Cash And Cash Equivalents [Line Items]
Amortized Cost	80,448
Unrealized Gains (Losses), Net	(215)
Recorded Basis	$ 80,233

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	$ 1,754	$ 3,517
Vaccine Development [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	700
UB-612 [Member] | Related Party [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	1,800
ELISA [Member] | Related Party [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	$ 1,700

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid materials and supplies	$ 1,754	$ 3,517
Deposits	1,323	614
Clinical prepayments	2,067	4,379
Other	358	341
Total	$ 5,502	$ 8,851

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 0.4	$ 0.4	$ 1.1	$ 0.9

Property and Equipment (Propert

Property and Equipment (Property and Equipment, Net) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment	$ 15,926	$ 14,353
Less accumulated depreciation	(3,125)	(1,981)
Property and equipment, net	12,801	12,372
Air Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	11,983	11,983
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	2,790	1,831
Fixed Assets Not Yet Placed Into Service [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	791	199
Software And Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	169,000	168,000
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	87,000	87,000
Furniture And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 106	$ 85

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Narrative) (Details) $ in Millions	Sep. 30, 2022 USD ($)
Accrued Expenses and Other Current Liabilities [Abstract]
Grant Monies Received	$ 3

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities (Accrued Expenses and Other Current Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued payroll and benefits	$ 3,842	$ 1,501
Accrued External Research And Development	3,410	2,294
Accrued professional fees and other	4,767	692
Accrued interest	30	32
Total	$ 12,049	$ 4,519

Other Long-Term Liabilities (Na

Other Long-Term Liabilities (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Accrued Payroll Taxes Current And Noncurrent	$ 0.2	$ 0.2

Other Long-Term Liabilities (Ot

Other Long-Term Liabilities (Other Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Accrued tax provision	$ 236	$ 236
Lease liability		1
Total	$ 236	$ 237

Notes payable (Notes payable wi

Notes payable (Notes payable with related parties) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Repayment of note payable with related party		$ (100)
Additions	$ (7)	$ (18)

Notes payable (Narrative) (Deta

Notes payable (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes payable with related parties				$ 2,000
Notes Payable, Airplane [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties					$ 11,500
Debt Instrument Interest Rate Stated Percentage					3.40%
Interest Expense, Debt	$ 100	$ 100	$ 300	$ 300
Debt Instrument Periodic Payment Interest			100
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid	9,400		9,400
Payments Of Debt Issuance Costs			300
Debt Instrument Increase Accrued Interest			100
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties	$ 300		$ 300

Notes payable (Carrying Value)

Notes payable (Carrying Value) (Details) - Note, 2025 [Member] - Notes Payable [Member] - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal	$ 10,564	$ 10,883
Unamortized debt issuance cost	145	184
Total	10,419	10,699
Less: current portion	(387)	(376)
Note payable, net of current portion and debt issuance cost	$ 10,032	$ 10,323

Notes payable (Annual Principal

Notes payable (Annual Principal Payments) (Details) - Note, 2025 [Member] - Notes Payable [Member] - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
2021	$ 109
2022	444
2023	458
2024	9,553
Total	$ 10,564	$ 10,883

Convertible Preferred Stock (Na

Convertible Preferred Stock (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares authorized/designated		50,000,000	50,000,000
Series B Preferred Stock [Member]
Class Of Stock [Line Items]
Conversion Of Stock, Per Share	$ 8
Conversion Of Stock Amount Issued 1	$ 122.9
Conversion Of Stock Shares Issued 1	15,365,574
Convertible Preferred Shares [Member] | UNS [Member]
Class Of Stock [Line Items]
Conversion Of Stock, Per Share	$ 0.2191
Convertible Preferred Shares [Member] | COVAXX [Member]
Class Of Stock [Line Items]
Conversion Of Stock, Per Share	$ 3.4233

Common Stock (Narrative) (Detai

Common Stock (Narrative) (Details) - $ / shares		9 Months Ended
	Nov. 15, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	6,000,000
Share Price	$ 13
Common stock, shares authorized		1,000,000,000		1,000,000,000
Common stock, par value		$ 0.0001		$ 0.0001
Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		100,000,000		100,000,000
Common stock, par value		$ 0.0001		$ 0.0001
Common Stock [Member] | Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares			485,836
Amended And Restated Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		1,100,000,000		1,100,000,000
Common stock, par value		$ 0.0001		$ 0.0001
Amended And Restated Common Stock [Member] | Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		1,000,000,000		1,000,000,000
Amended And Restated Common Stock [Member] | Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		100,000,000		100,000,000
UNS [Member] | Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares		60,360,523
Shares converted		0.2191
UNS [Member] | Common Class B [Member]
Class Of Stock [Line Items]
Issuance of stock, shares		10,999,149
Shares converted		3.4233

Common Stock (Reserved Share of

Common Stock (Reserved Share of Common Stock for Issuance) (Details) - shares	Sep. 30, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Options issued and outstanding	20,293,681	21,387,909
Options [Member]
Class Of Stock [Line Items]
Options issued and outstanding	20,593,681	21,387,909
Options available for future grants	6,251,916	7,209,538
Warrants issued and outstanding to purchase shares of common stock	1,928,020	1,928,020
Reserved Shares of Common Stock	28,773,617	30,525,467

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	20,293,681		20,293,681		21,387,909
Options exercisable	13,977,398		13,977,398
Total stock-based compensation expense	$ 2,357	$ 1,464	$ 6,361	$ 5,602
Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant	6,251,916		6,251,916		7,209,538
Options outstanding	20,593,681		20,593,681		21,387,909
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant-date fair value per share of options granted			$ 3.76
Class A Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan	8,700,000		8,700,000
Percent, Shares Outstanding	4%		4%
Class A Common Stock [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense			$ 100
2021 Stock Option and Grant Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost	$ 18,900		$ 18,900
Recognized over a weighted average period			2 years 6 months
2021 Stock Option and Grant Plan [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant	6,251,916		6,251,916
Intrincic value of options exercised			$ 4,500
Weighted-average grant-date fair value per share of options granted			$ 2.38
2021 Stock Option and Grant Plan [Member] | Class A Common Stock [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	13,931,226		13,931,226
Options exercisable	9,032,635		9,032,635
2021 Stock Option and Grant Plan [Member] | Common Class B [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	6,362,455		6,362,455
Options exercisable	4,944,763		4,944,763

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stock-Based Compensation [Abstract]
Number of stock options, outstanding	21,387,909
Number of stock options, Granted	1,104,921
Number of stock options, Exercised	(1,065,706)
Number of stock options, Forfeited	(1,133,443)
Number of stock options, outstanding	20,293,681	21,387,909
Number of stock options, Exercisable	13,977,398
Weighted price per share, outstanding	$ 5.25
Weighted price per share, Granted	3.19
Weighted price per share, Exercised	3.26
Weighted price per share, Forfeited	7.23
Weighted price per share, outstanding	5.13	$ 5.25
Weighted price per share,exercisable	$ 4.52
Weighted contractual term, outstanding	7 years 1 month 6 days	7 years 4 months 24 days
Weighted contractual term, exercisable	6 years 9 months 18 days
Aggregate intrinsic value, outstanding	$ 11,940	$ 49,684
Aggregate intrinsic value, exercisable	$ 10,773

Stock-Based Compensation (Sum_2

Stock-Based Compensation (Summary of Restricted Stock Activity) (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross	1,104,921
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross	300,000
Unvested, Number of Shares, Ending Balance	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 3.76

Stock-Based Compensation (Sched

Stock-Based Compensation (Schedule of Stock-Based Compensation Expense for Stock Options) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 2,357	$ 1,464	$ 6,361	$ 5,602
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	848	364	2,473	738
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,509	$ 1,100	$ 3,888	$ 4,864

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Continuing Operations	0%	0%

Net Loss Per Share (Schedule of

Net Loss Per Share (Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share) (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	22,521,701	72,635,150
Options issued and outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	20,593,681	20,714,308
Warrants issued and outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	1,928,020	2,056,722
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share		39,989,083
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share		9,875,037

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) $ in Millions	1 Months Ended		3 Months Ended	9 Months Ended
	Apr. 30, 2022 USD ($)	Aug. 31, 2021 USD ($)	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2022 USD ($) ft²
Commitments And Contingencies [Line Items]
Lease in square feet | ft²			4,419	4,419
Project Grant				$ 0.8
Grant, Accrued Liability, NonCurrent			$ 0.1	0.1
Short Term Lease Payments			0.1	0.3
Variable Lease Payment			0.1	0.1
Restricted Cash And Current Accrued Liability			3	3
Reduction In Research And Development			1.6	3.1
Materials Ordered		$ 7.2	0.4	0.4
Materials Expensed		1.2
Materials Received		$ 3
Materials Delivered			0.8	0.8
Materials On Order			3	3
Materials, Probable Loss				2.6
Contract Research Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments			3.1	3.1
Contract Manufacturing Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments			$ 0.7	$ 0.7
UB-612 [Member]
Commitments And Contingencies [Line Items]
Project Grant	$ 9.3

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details) - Foreign Plan [Member] - Personal Retirement Savings Account [Member] - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Defined Contribution Plan Disclosure [Line Items]
Company contribution percent	4%
Company contributions	$ 0.1	$ 0.1

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Due to related parties	$ 16,700		$ 16,700		$ 19,400
Service fees	0	$ 13,900	1,100	$ 32,600
Prepaid expenses	5,502		5,502		8,851
Due From Related Parties	$ 400		$ 400		$ 400
UBI [Member] | UBI1 [Member]
Related Party Transaction [Line Items]
Percent of ownership	44%		44%

Related Party Transactions (Sch

Related Party Transactions (Schedule of Related Party Operating Activity) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Prepaid expenses and other current assets			$ 5,502		$ 8,851
Due From Related Parties			400		400
Property and equipment, net			12,801		12,372
Due to related parties			16,700		19,400
Revenue	$ 50			$ 67
Cost of revenue		$ 9		1,937
Services Provided By Related Parties [Member]
Related Party Transaction [Line Items]
Research and development		13,515	1,139	38,667
General and administrative		$ 355		1,173
Taiwan CDC Grant [Member]
Related Party Transaction [Line Items]
Research and development				$ (7,199)
UBI IP [Member] | Services Provided By Related Parties [Member]
Related Party Transaction [Line Items]
Prepaid expenses and other current assets			1,743		3,517
Due From Related Parties			400		393
Property and equipment, net					337
Due to related parties			16,676		$ 19,407
Accrued expenses			$ 877